Access brought to you by: LOCKSS

Diabetes & Endocrinology Clinical Trials

Patient Involvement in Diabetes Care: Greek Study of Decision Aids Inconclusive
IDegLira Offers Advantages over IDeg and Liraglutide in T2DM: DUAL I Results
Once Weekly Exenatide is Safe and Effective for Long-term T2DM Treatment
GLUCO-CABG: No Reduction in Perioperative Complications to Cardiac Surgery with Intensive Control of Hyperglycemia
Effects of PDE-5 Inhibition in Patients with T2DM
Novel Once-Weekly Omarigliptin as Effective and Well Tolerated as Once-Daily Sitagliptin in Japanese Patients
Combined Saxagliptin and Dapagliflozin Reduce Blood Glucose Levels in T2DM Patients
Long-term Canagliflozin is Efficacious and Generally Well Tolerated in Older Patients
Combining Empagliflozin and Linagliptin with Metformin Reduces HbA_1c in Patients with T2DM
Empagliflozin Superior to Glimepiride as Second-line Treatment in T2DM

Pages